Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913002 · ClinicalTrials.gov registry record · Phase 1
Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01913002 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 63 participants.
The verdict
NCT01913002, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000 mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
Interventions
- DRUG LX4211 800 mg
- DRUG LX4211 2000 mg
- DRUG moxifloxacin 400 mg
- DRUG LX4211 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01913002
The ClinicalTrials.gov registry entry for NCT01913002 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LX4211 800 mg is the first listed.
NCT01913002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01913002 about?
NCT01913002 is a clinical study titled "Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects". This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000 mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
What is the current status of trial NCT01913002?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2013-07.
What interventions are being tested in trial NCT01913002?
The interventions under investigation include: LX4211 800 mg (DRUG), LX4211 2000 mg (DRUG), moxifloxacin 400 mg (DRUG), LX4211 Placebo (DRUG).
Who is sponsoring clinical trial NCT01913002?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.